338 related articles for article (PubMed ID: 18930726)
21. Tachykinin NK(3)receptor involvement in anxiety.
Ribeiro SJ; Teixeira RM; Calixto JB; De Lima TC
Neuropeptides; 1999 Apr; 33(2):181-8. PubMed ID: 10657489
[TBL] [Abstract][Full Text] [Related]
22. Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization.
Malherbe P; Knoflach F; Marcuz A; Bohnert C; Weber M; Knust H; Ratni H; Spooren W; Ballard TM; Bissantz C
Neuropharmacology; 2014 Nov; 86():259-72. PubMed ID: 25107588
[TBL] [Abstract][Full Text] [Related]
23. Central neurokinin 3 receptors increase systemic oxytocin release: interaction with norepinephrine.
Bealer SL; Flynn FW
Exp Neurol; 2003 Dec; 184(2):1027-33. PubMed ID: 14769397
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
[TBL] [Abstract][Full Text] [Related]
25. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
26. Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation.
Jung M; Michaud JC; Steinberg R; Barnouin MC; Hayar A; Mons G; Souilhac J; Emonds-Alt X; Soubrié P; Le Fur G
Neuroscience; 1996 Sep; 74(2):403-14. PubMed ID: 8865192
[TBL] [Abstract][Full Text] [Related]
27. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
28. Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils.
Bristow LJ; Young L
Eur J Pharmacol; 1994 Mar; 253(3):245-52. PubMed ID: 7515350
[TBL] [Abstract][Full Text] [Related]
29. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M
Neuro Endocrinol Lett; 2005 Aug; 26(4):367-72. PubMed ID: 16136007
[TBL] [Abstract][Full Text] [Related]
30. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.
Brocco M; Dekeyne A; Mannoury la Cour C; Touzard M; Girardon S; Veiga S; de Nanteuil G; deJong TR; Olivier B; Millan MJ
Eur Neuropsychopharmacol; 2008 Oct; 18(10):729-50. PubMed ID: 18657401
[TBL] [Abstract][Full Text] [Related]
31. Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer.
Jordan RE; Smart D; Grimson P; Suman-Chauhan N; McKnight AT
Br J Pharmacol; 1998 Oct; 125(4):761-6. PubMed ID: 9831912
[TBL] [Abstract][Full Text] [Related]
32. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
Malherbe P; Knoflach F; Hernandez MC; Hoffmann T; Schnider P; Porter RH; Wettstein JG; Ballard TM; Spooren W; Steward L
Br J Pharmacol; 2011 Feb; 162(4):929-46. PubMed ID: 21039418
[TBL] [Abstract][Full Text] [Related]
33. Modulation of cardiac activity by tachykinins in the rat substantia nigra.
Lessard A; Couture R
Br J Pharmacol; 2001 Dec; 134(8):1749-59. PubMed ID: 11739252
[TBL] [Abstract][Full Text] [Related]
34. SR142801 behaves as a tachykinin NK-3 receptor agonist on a spinal nociceptive reflex in the rat.
Couture R; Toma N; Barbot L
Life Sci; 2000; 66(1):51-65. PubMed ID: 10658924
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological examination of the neurokinin-1 receptor mediating relaxation of human intralobar pulmonary artery.
Pedersen KE; Buckner CK; Meeker SN; Undem BJ
J Pharmacol Exp Ther; 2000 Jan; 292(1):319-25. PubMed ID: 10604965
[TBL] [Abstract][Full Text] [Related]
36. NK(3) receptor agonism promotes episodic-like memory in mice.
Zlomuzica A; Dere E; Huston JP; de Souza Silva MA
Neurobiol Learn Mem; 2008 Sep; 90(2):420-5. PubMed ID: 18556225
[TBL] [Abstract][Full Text] [Related]
37. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
38. Central administration of senktide, a tachykinin NK-3 agonist, has an antidiuretic action by stimulating AVP release in water-loaded rats.
Saigo A; Takano Y; Matsumoto T; Tran M; Nakayama Y; Saito R; Yamada K; Kamiya H
Neurosci Lett; 1993 Sep; 159(1-2):187-90. PubMed ID: 7505413
[TBL] [Abstract][Full Text] [Related]
39. Tachykinin-depolarizations mediated by neurokinin-3 receptors in the hamster submandibular ganglion cells.
Yamada T; Endoh T; Suzuki T
Bull Tokyo Dent Coll; 1998 May; 39(2):123-6. PubMed ID: 9667146
[TBL] [Abstract][Full Text] [Related]
40. Desensitization with a selective agonist discriminates between multiple tachykinin receptors.
Laufer R; Gilon C; Chorev M; Selinger Z
J Pharmacol Exp Ther; 1988 May; 245(2):639-43. PubMed ID: 2835478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
